Puretech Health - News & Press
WEB6 days ago — Press releases. 2024-09-06. PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies. Continue.
FDA approves PureTech’s KarXT to treat schizophrenia in adults
WEB3 days ago — PRTC. PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in adults. With this approval, the company is entitled to receive two ...
PureTech-Invented KarXT Receives U.S. Food and Drug …
WEB6 days ago — The FDA approval triggers two separate milestone payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was...
PureTech to Present at CHEST 2024 Annual Meeting - Yahoo …
WEB2 days ago — BOSTON, October 01, 2024 -- (BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives ...
PureTech News
WEBMar 4, 2024 — PureTech News. Validating the efficacy and value proposition of mental fitness vocal biomarkers in a psychiatric population: prospective cohort study. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection.
News Release Details - PureTech Health
WEBBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion. Acquisition centered on KarXT, which was invented at PureTech, as a potential first-in-class treatment for schizophrenia in adults. PureTech to receive approximately $293 million gross proceeds from Karuna equity position in …
PureTech to Present at CHEST 2024 Annual Meeting
WEB2 days ago — 2024-10-01. RNS Number : 3440G. PureTech Health PLC. 01 October 2024. PureTech to Present at CHEST 2024 Annual Meeting. Three presentations inform clinical, commercial and patient engagement strategies for LYT-100 for the treatment of idiopathic pulmonary fibrosis (IPF) Topline data from the Phase 2b ELEVATE IPF trial of LYT-100 expected by the ...
News Release Details - PureTech Health
WEBAug 1, 2023 — PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the company has been awarded up to $11.4 million from the U.S. Department of Defense (DoD) to advance its therapeutic candidate, LYT-300 ...
PureTech News | PureTech Health
WEBAug 28, 2024 — PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
PureTech Health (PRTC) Gets a Buy from Leerink Partners
WEB2 days ago — PureTech Health has an analyst consensus of Moderate Buy. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $34.00 and a one-year low of $17.08.
- Some results have been removed